Abstract
There is a pressing need for antiviral agents that are effective against multiple classes of viruses. Broad specificity might be achieved by targeting phospholipids that are widely expressed on infected host cells or viral envelopes. We reasoned that events occurring during virus replication (for example, cell activation or preapoptotic changes) would trigger the exposure of normally intracellular anionic phospholipids on the outer surface of virus-infected cells. A chimeric antibody, bavituximab, was used to identify and target the exposed anionic phospholipids. Infection of cells with Pichinde virus (a model for Lassa fever virus, a potential bioterrorism agent) led to the exposure of anionic phospholipids. Bavituximab treatment cured overt disease in guinea pigs lethally infected with Pichinde virus. Direct clearance of infectious virus from the blood and antibody-dependent cellular cytotoxicity of virus-infected cells seemed to be the major antiviral mechanisms. Combination therapy with bavituximab and ribavirin was more effective than either drug alone. Bavituximab also bound to cells infected with multiple other viruses and rescued mice with lethal mouse cytomegalovirus infections. Targeting exposed anionic phospholipids with bavituximab seems to be safe and effective. Our study demonstrates that anionic phospholipids on infected host cells and virions may provide a new target for the generation of antiviral agents.
This is a preview of subscription content
Access options
Subscribe to Journal
Get full journal access for 1 year
$59.00
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Buy article
Get time limited or full article access on ReadCube.
$32.00
All prices are NET prices.




References
Williamson, P. & Schlegel, R.A. Back and forth: the regulation and function of transbilayer phospholipid movement in eukaryotic cells. Mol. Membr. Biol. 11, 199–216 (1994).
Zwaal, R.F. & Schroit, A.J. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood 89, 1121–1132 (1997).
Seigneuret, M. & Devaux, P.F. ATP-dependent asymmetric distribution of spin-labeled phospholipids in the erythrocyte membrane: relation to shape changes. Proc. Natl. Acad. Sci. USA 81, 3751–3755 (1984).
Balasubramanian, K. & Schroit, A.J. Aminophospholipid asymmetry: A matter of life and death. Annu. Rev. Physiol. 65, 701–734 (2003).
Daleke, D.L. Regulation of transbilayer plasma membrane phospholipid asymmetry. J. Lipid Res. 44, 233–242 (2003).
Holthuis, J.C. & Levine, T.P. Lipid traffic: floppy drives and a superhighway. Nat. Rev. Mol. Cell Biol. 6, 209–220 (2005).
Simmons, A., Aluvihare, V. & McMichael, A. Nef triggers a transcriptional program in T cells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity 14, 763–777 (2001).
Rawls, W.E., Banerjee, S.N., McMillan, C.A. & Buchmeier, M.J. Inhibition of Pichinde virus replication by actinomycin D. J. Gen. Virol. 33, 421–434 (1976).
Lukashevich, I.S., Lemeshko, N.N. & Shkolina, T.V. Effect of actinomycin D on the reproduction of the Machupo virus. Vopr. Virusol. 29, 569–572 (1984).
Choe, W., Volsky, D.J. & Potash, M.J. Activation of NF-κB by R5 and X4 human immunodeficiency virus type 1 induces macrophage inflammatory protein 1alpha and tumor necrosis factor alpha in macrophages. J. Virol. 76, 5274–5277 (2002).
Takizawa, T. et al. Induction of programmed cell death (apoptosis) by influenza virus infection in tissue culture cells. J. Gen. Virol. 74, 2347–2355 (1993).
Banki, K., Hutter, E., Gonchoroff, N.J. & Perl, A. Molecular ordering in HIV-induced apoptosis. Oxidative stress, activation of caspases and cell survival are regulated by transaldolase. J. Biol. Chem. 273, 11944–11953 (1998).
Gautier, I., Coppey, J. & Durieux, C. Early apoptosis-related changes triggered by HSV-1 in individual neuronlike cells. Exp. Cell Res. 289, 174–183 (2003).
Mercer, J. & Helenius, A. Vaccinia virus uses macropinocytosis and apoptotic mimicry to enter host cells. Science 320, 531–535 (2008).
Ran, S. et al. Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice. Clin. Cancer Res. 11, 1551–1562 (2005).
Luster, T.A. et al. Plasma protein β-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells. J. Biol. Chem. 281, 29863–29871 (2006).
Jahrling, P.B., Hesse, R.A., Rhoderick, J.B., Elwell, M.A. & Moe, J.B. Pathogenesis of a pichinde virus strain adapted to produce lethal infections in guinea pigs. Infect. Immun. 32, 872–880 (1981).
Huang, R.T., Lichtenberg, B. & Rick, O. Involvement of annexin V in the entry of influenza viruses and role of phospholipids in infection. FEBS Lett. 392, 59–62 (1996).
Callahan, M.K. et al. Phosphatidylserine on HIV envelope is a cofactor for infection of monocytic cells. J. Immunol. 170, 4840–4845 (2003).
Briggs, J.A.G., Wilk, T. & Fuller, S.D. Do lipid rafts mediate virus assembly and pseudotyping? J. Gen. Virol. 84, 757–768 (2003).
Ono, A. & Freed, E.O. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc. Natl. Acad. Sci. USA 98, 13925–13930 (2001).
Scheiffele, P., Rietveld, A., Wilk, T. & Simons, K. Influenza viruses select ordered lipid domains during budding from the plasma membrane. J. Biol. Chem. 274, 2038–2044 (1999).
Pickl, W.F., Pimentel-Muinos, F.X. & Seed, B. Lipid rafts and pseudotyping. J. Virol. 75, 7175–7183 (2001).
Bavari, S. et al. Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. J. Exp. Med. 195, 593–602 (2002).
Brown, G., Rixon, H.W. & Sugrue, R.J. Respiratory syncytial virus assembly occurs in GM1-rich regions of the host-cell membrane and alters the cellular distribution of tyrosine phosphorylated caveolin-1. J. Gen. Virol. 83, 1841–1850 (2002).
Pike, L.J., Han, X., Chung, K.N. & Gross, R.W. Lipid rafts are enriched in arachidonic acid and plasmenylethanolamine and their composition is independent of caveolin-1 expression: a quantitative electrospray ionization/mass spectrometric analysis. Biochemistry 41, 2075–2088 (2002).
Bakht, O., Pathak, P. & London, E. Effect of the structure of lipids favoring disordered domain formation on the stability of cholesterol-containing ordered domains (lipid rafts): identification of multiple raft-stabilization mechanisms. Biophys. J. 93, 4307–4318 (2007).
Dillon, S.R., Mancini, M., Rosen, A. & Schlissel, M.S. Annexin V binds to viable B cells and colocalizes with a marker of lipid rafts upon B cell receptor activation. J. Immunol. 164, 1322–1332 (2000).
Frasch, S.C. et al. Phospholipid flip-flop and phospholipid scramblase 1 (PLSCR1) co-localize to uropod rafts in formylated Met-Leu-Phe–stimulated neutrophils. J. Biol. Chem. 279, 17625–17633 (2004).
Sutherland, M.R., Raynor, C.M., Leenknegt, H., Wright, J.F. & Pryzdial, E.L. Coagulation initiated on herpesviruses. Proc. Natl. Acad. Sci. USA 94, 13510–13514 (1997).
Pryzdial, E.L. & Wright, J.F. Prothrombinase assembly on an enveloped virus: evidence that the cytomegalovirus surface contains procoagulant phospholipid. Blood 84, 3749–3757 (1994).
Sanchez, V. & Spector, D.H. Virology. CMV makes a timely exit. Science 297, 778–779 (2002).
de Laat, B., Derksen, R.H., van Lummel, M., Pennings, M.T. & de Groot, P.G. Pathogenic anti–β2-glycoprotein I antibodies recognize domain I of β2-glycoprotein I only after a conformational change. Blood 107, 1916–1924 (2006).
Godofsky, E.W. & Shan, J. Phase 1 single dose study of bavituximab, a chimeric anti-phosphatidylserine monoclonal antibody, in subjects with chronic hepatitis C. Hepatology 44, 236A (2006).
Lawitz, E., Godofsky, E. & Shan, J. Multiple dose safety and pharmacokinetic study of bavituximab, a chimeric anti-phosphatidylserine monoclonal antibody, in subjects with chronic hepatitis C virus (HCV) infection. Hepatology 46, 257A (2007).
Chen, X., Doffek, K., Sugg, S.L. & Shilyansky, J. Phosphatidylserine regulates the maturation of human dendritic cells. J. Immunol. 173, 2985–2994 (2004).
Fadok, V.A. et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-β, PGE2, and PAF. J. Clin. Invest. 101, 890–898 (1998).
Hoffmann, P.R. et al. Interaction between phosphatidylserine and the phosphatidylserine receptor inhibits immune responses in vivo. J. Immunol. 174, 1393–1404 (2005).
Ferguson, T.A. et al. Uptake of apoptotic antigen-coupled cells by lymphoid dendritic cells and cross-priming of CD8+ T cells produce active immune unresponsiveness. J. Immunol. 168, 5589–5595 (2002).
Marconescu, A. & Thorpe, P.E. Coincident exposure of phosphatidylserine and anionic phospholipids on the surface of irradiated cells. Biochim. Biophys. Acta 1778, 2217–2224.
Acknowledgements
Rabbit Pichinde-specific antiserum was a gift from J. Aronson, University of Texas Medical Branch, Galveston. This work was supported by a US National Institutes of Health grant (5 U01 AI1056412) and a sponsored research agreement with Peregrine Pharmaceuticals. We thank G. Barbero, S. Mims, H. Arizpe, L. Ingram, S. Syed, L. Watkins, S. Li and J. Iglehart for technical assistance. We also thank W. Bresnahan, S. Ran, O. Ramilo, H. Jafri, S. Fussey, M. Roth and J. Albanesi for discussions and comments on the manuscript.
Author information
Authors and Affiliations
Contributions
M.M.S. designed and supervised experiments, interpreted results and wrote the manuscript. S.W.K. provided reagents and contributed to experimental design and interpretation of results. P.E.T. conceived the idea of phosphatidylserine-directed antiviral therapy, oversaw experiments and wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
M.M.S. holds Peregrine Pharmaceuticals Inc. stock, S.W.K. is employed by Peregrine Pharmaceuticals, and P.E.T. is a consultant, stock holder and has sponsored a research agreement with Peregrine Pharmaceuticals. The company is commercially developing bavituximab for the treatment of virus infections.
Supplementary information
Supplementary Text and Figures
Supplementary Figs. 1–7 (PDF 2825 kb)
Rights and permissions
About this article
Cite this article
Soares, M., King, S. & Thorpe, P. Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. Nat Med 14, 1357–1362 (2008). https://doi.org/10.1038/nm.1885
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.1885
Further reading
-
Phosphatidylserine externalized on the colonic capillaries as a novel pharmacological target for IBD therapy
Signal Transduction and Targeted Therapy (2021)
-
Monoklonale Antikörper zur antiinfektiven Therapie
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz (2020)
-
Various Facets of Pathogenic Lipids in Infectious Diseases: Exploring Virulent Lipid-Host Interactome and Their Druggability
The Journal of Membrane Biology (2020)
-
Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer
Cell Death & Differentiation (2016)
-
Functional organization of the HIV lipid envelope
Scientific Reports (2016)